Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.28Last Year’s EPS
0.88Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -6.54%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
Valneva had a successful year with achieved sales growth, a solid cash position, and strong regulatory and R&D progress. However, challenges such as delayed approvals and slower than expected market dynamics for IXCHIQ contribute to a balanced outlook.Company Guidance
In the earnings call, Valneva provided guidance for 2025, highlighting several key metrics and strategic objectives. The company projected total product sales to reach between €170 million and €180 million, with overall revenues expected to be in the range of €180 million to €190 million. This growth is mainly attributed to increased sales of IXCHIQ, especially in the U.S., and expansion into new territories. The company also expects a significant increase in research and development expenses, estimated to reach between €90 million and €100 million, driven by ongoing clinical trials, notably their chikungunya vaccine Phase 4 trial and the newly licensed Phase 2 Shigella vaccine candidate. Valneva reported a solid cash position of €168 million at the end of 2024 and aims to reduce its operational cash burn by over 50% in 2025. Looking ahead, Valneva anticipates a transformative potential for their Lyme disease vaccine candidate, VLA15, which is currently in Phase 3, with a first data readout expected by the end of 2025, followed by regulatory filings in 2026 and potential market entry by 2028.Achieved Double-Digit Sales Growth
Valneva achieved their targeted double-digit year-on-year sales growth with sales above €160 million, aligned with their 2024 guidance.
Strong Cash Position
Valneva reported a strong cash position at year-end, close to €170 million, with a significantly lower operating cash burn.
Regulatory Success and Pipeline Expansion
Valneva received three additional IXCHIQ approvals and expanded their pipeline with a leading Phase 2 Shigella program.
Positive Financial Performance Indicators
Valneva reported an operating profit of €20.7 million in 2024 compared with an operating loss of €82.1 million in the prior year.
Significant R&D Investments
The company increased R&D investments, notably in Phase 4 trials for chikungunya and a new Shigella program, supported by external grant funding.
---
VALN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VALN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $6.73 | $7.25 | +7.73% |
| Nov 07, 2024 | $5.59 | $5.48 | -1.97% |
| Aug 13, 2024 | $6.94 | $7.45 | +7.35% |
| May 07, 2024 | $7.50 | $7.50 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Valneva (VALN) report earnings?
Valneva (VALN) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Valneva (VALN) earnings time?
Valneva (VALN) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VALN EPS forecast?
VALN EPS forecast for the fiscal quarter 2025 (Q1) is -0.28.
---